An Open-Label, Single- and Multi-Dose Pharmacokinetic (PK) Study of Oral Diltiazem and Topical Diltiazem Hydrochloride

Status unconfirmed · Phase 1

Conditions studied: Adult Subjects With Anal Fissures.

In brief

The study is a single-center, open-label, safety and pharmacokinetic study in12 adult subjects with Anal Fissures. Subjects will be screened to determine eligibility within 7 days of treatment. There will be three parts to the study and all subjects will participate in each part.

Key facts

Study ID

NCT01816191

Run by

Ventrus Biosciences, Inc

People needed

12

Starts

2013-02-01

Expected to finish

2013-09-01

Last updated by the study team

2013-08-21

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with evidence of a circumscribed anal fissure, with induration at the edges.
• Any female of non-childbearing potential who:
• a) has had a hysterectomy, b) has had a bilateral oophorectomy, c) has had a bilateral tubal ligation or d) is post-menopausal (demonstration of total cessation of menses for ≥ 1 year from the date of the screening visit).
• Any female of child bearing potential must agree to use at least one form of contraception(may be a barrier method), during the full duration of the study.
• Able to communicate adequately with the investigator and to comply with the requirements for the entire study.
• Capable of and freely willing to provide written informed consent prior to participating in the study.

You may not qualify if…

• Unwilling to have visual or medical examination of the Anal Fissure.
• More than 1 Anal Fissure.
• Subjects with Anal Fissure associated with or caused by other conditions, including but not limited to: drug-induced, trauma, HIV infection, fistula-in-ano, inflammatory bowel disease, perianal sepsis or malignancy.
• Unwilling to stop all other concomitant topical preparations applied in and around the anus from Day -1 through end of the study.
• Use of sitz bath from signing of ICF (Informed Consent Form) to end of study.
• Use of anesthetics from signing the ICF to end of study.
• Subfissure injection of botulinum toxin in the 3 months prior to signing the ICF.
• Known sensitivity to investigational product(s) or calcium channel blockers.
• Active treatment with anti-viral therapies for HIV (e.g. indinavir, nelfinivir,ritonavir).
• Treatment with any prohibited medications within 14 days prior to signing the ICF:
• Cytochrome P450 (CYP450) inhibitors and inducers
• Cytochrome P3A4 (CYP3A4) substrates, inhibitors, and inducers
• Benzodiazepines
• β-adrenoceptor antagonists (Beta-Blockers)
• Calcium channel blockers
• Digoxin
• Investigational agents
• Opioids
• Following concomitant disease state:
• Sick sinus syndrome except in the presence of a functioning ventricular pacemaker.
• Second-or third-degree Atrioventricular block except in the presence of a functioning ventricular pacemaker.
• Hypotension (less than 90 mm Hg systolic).
• Acute myocardial infarction and pulmonary congestion documented by x-ray.
• History of clinically significant renal disease.
• History of clinically significant Alzheimer's or Parkinson's disease.

Where it is running

• Wake Research Associates — Raleigh, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.